OnKure Therapeutics Inc. (OKUR)
6.41
0.03 (0.47%)
At close: Jan 15, 2025, 9:50 AM
Company Description
OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer.
The company focuses on developing selective inhibitors of histone deacetylases.
Its portfolio includes OKI-179, an inhibitor for the treatment of both hematological and solid tumors.
The company was incorporated in 2011 and is based in Boulder, Colorado.
OnKure Therapeutics Inc.
| Country | United States |
| IPO Date | n/a |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 50 |
| CEO | Dr. Nicholas A. Saccomano Ph.D. |
Contact Details
Address: 6707 Winchester Circle Boulder, Colorado United States | |
| Website | https://onkuretherapeutics.com |
Stock Details
| Ticker Symbol | n/a |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | n/a |
| CUSIP Number | n/a |
| ISIN Number | US68277Q1058 |
| Employer ID | - |
| SIC Code | n/a |
Key Executives
| Name | Position |
|---|---|
| Dr. Nicholas A. Saccomano Ph.D. | President, Chief Executive Officer & Director |
| Jason A. Leverone CPA | Chief Financial Officer |
| Dr. Duncan Walker Ph.D. | Chief Development Officer |
| Dr. Dylan Hartley Ph.D. | Chief Scientific Officer |
| Dr. James Blake Ph.D. | Senior Vice President of Computational Drug Discovery |
| Dr. Kevin S. Litwiler Ph.D. | Senior Vice President of DMPK & Clinical Pharmacology |
| Dr. Mark L. Boys Ph.D. | Senior Vice President of Discovery Chemistry |
| Dr. Samuel Agresta M.D., M.P.H. | Chief Medical Officer |
| Rogan P. Nunn J.D. | General Counsel & Secretary |